Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Tumor》 2017-08
Add to Favorite Get Latest Update

Research progress in preclinical cancer models

YU Suyun;WANG Siliang;JIA Qi;CHEN Lichuan;CHEN Wenxing;WANG Aiyun;LU Yin;Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica,School of Pharmacy,Nanjing University of Chinese Medicine;Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor,Nanjing University of Chinese Medicine;  
Along with the increase in incidence and mortality of cancer,cancer has become a threat to human health. Therefore,more and more researchers have devoted themselves to the exploration of the pathogenesis of cancer and the related new therapies. Even so, only a few new anticancer drugs have been approved every year, the main reason is that the vast majority of new drugs has better preclinical effect but not has good clinical curative effect, so the reasonable application and innovation of preclinical evaluation system of antineoplastic drugs and the combination and unification of preclinical studies and clinical efficacy are urgent and important. It is well known that animal cancer models play an important role in the pathogenesis and treatment of cancer. This paper discusses the prospect of the most commonly used mouse models of cancer in preclinical studies and the challenges, and introduces the prospect of the new cancer models, in order to provide references for rational evaluation of clinical efficacy of drugs.
【Fund】: 国家自然科学基金资助项目(编号:81673725、81673648);; 中国博士后科学基金面上资助项目(编号:2014M551639);; 江苏省自然科学基金面上研究项目(编号:BK2012854);; 江苏高校优势学科建设工程一期项目;; 2013年度江苏高校优秀科技创新团队~~
【CateGory Index】: R-332;R73-3
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved